权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Botswana CASCADE Clinical Trials Site

博茨瓦纳 CASCADE 临床试验现场

基本信息

批准号：
10544424
负责人：
Scott Dryden-Peterson
金额：
$ 25.78万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-05 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10544424
关键词：
AIDS clinical trial group AIDS related cancer Ablation Acquired Immunodeficiency Syndrome Africa African Area Botswana COVID-19 Prevention Network Caring Cause of Death Cervical Cervical dysplasia Cessation of life Clinical Research Clinical Trials Clinical Trials Network Clinical Trials Unit Collaborations Communities Community Health Education Consumption Country Cryptococcosis Data Devices Dysplasia Early Diagnosis Early treatment Economic Factors Effectiveness Enrollment Ethics Ethnic Origin Evaluation Female Adolescents Geography HIV HIV diagnosis Health Services Accessibility Health system High Prevalence Human Papilloma Virus Vaccination Human Papillomavirus Immunotherapy Impairment Improve Access Income Institutes International International Agencies International Maternal Pediatric Adolescent AIDS Clinical Trials Laboratories Language Lesion Malignant Neoplasms Malignant neoplasm of cervix uteri Mentors Observational Study Oncology Outcome Participant Patient Recruitments Patient risk Patients Performance Persons Population Prevalence Prevention Preventive service Protocols documentation Quality Control Relapse Research Research Personnel Resources Sampling Site Southern Africa Target Populations Techniques Technology Time Training Treatment Effectiveness Tuberculosis United States National Institutes of Health Universal Coverage Vaccines Viral Woman aged antenatal care antiretroviral therapy breast cancer diagnosis cancer diagnosis cancer invasiveness cancer prevention cancer therapy clinical research site cohort community engagement comparative trial data management data quality effectiveness evaluation experience improved innovation mortality new technology novel pragmatic trial premalignant prevent programs prospective quality assurance randomized trial research study screening screening program treatment optimization treatment program uptake

项目摘要

Project Summary / Abstract Successful HIV treatment programs in Botswana and elsewhere in southern Africa have led to dramatic reductions in mortality from tuberculosis, cryptococcosis, and other non-cancer AIDS deaths. However, cancer deaths have not decreased, and cervical cancer now is the leading cause of death for women living with HIV in the region. Cervical cancer is preventable with early detection and treatment of precancerous lesions but challenges of limited access to initial screening, poor performance of initial screening technologies, high prevalence of cervical precancers, and persistent or relapsed dysplasia following therapy impair the impact of programs for women living with HIV. Working to develop strategies to these challenges, we will establish the Botswana CASCADE Clinical Trials Site at BHP that will participate in and contribute to the following high- impact areas of research: 1) Enhancing cervical precancer screening uptake through patient and context relevant approaches, including HPV self-sampling, non-clinical screening venues, and screening during antenatal care; 2) Strategies and novel technologies to improve management of positive HPV initial screening maximize prevention of invasive cancer while minimizing patient risk and consumption of health system resources; 3) Improving precancer treatment access, treatment completion, and outcomes; and 4) Optimizing treatment approaches to cervical precancers including comparative trials of ablation techniques, intervals of repeat evaluation, and vaccines or other immunologic therapies. The Botswana CASCADE Clinical Trials Site will contribute to conducting high-quality clinical research studies, provide context-relevant input on developing trial concepts, understand disparity in access by geography, economic factors, and language/ethnicity, and continue to develop local research capacity through mentoring and training.

项目总结/摘要博茨瓦纳和南部非洲其他地方成功的艾滋病毒治疗项目导致了戏剧性的减少结核病、隐球菌病和其他非癌症艾滋病死亡的死亡率。然而，癌症死亡人数没有减少，宫颈癌现在是艾滋病毒感染妇女死亡的主要原因，本地区宫颈癌可以通过早期发现和治疗癌前病变来预防，获得初步筛查的机会有限，初步筛查技术的性能差，宫颈癌前病变的患病率以及治疗后持续或复发的异型增生削弱了艾滋病毒感染者的方案。为了制定应对这些挑战的战略，我们将建立博茨瓦纳CASCADE临床试验基地在必和必拓，将参与并有助于以下高- 研究的影响领域：1）通过患者和背景加强宫颈癌前筛查的吸收相关方法，包括HPV自我采样、非临床筛查场所和产前保健; 2）改善HPV阳性初始筛查管理的战略和新技术最大限度地预防侵袭性癌症，同时最大限度地减少患者风险和卫生系统消耗资源; 3）改善癌前治疗的获得，治疗完成和结果;以及4）优化宫颈癌前病变的治疗方法，包括消融技术的比较试验，重复评估和疫苗或其他免疫疗法。博茨瓦纳CASCADE临床试验网站将有助于开展高质量的临床研究，提供与背景相关的输入，发展试验概念，了解地理、经济因素和在这方面，教科文组织将继续加强对语言/族裔的研究，并继续通过辅导和培训发展当地的研究能力。